Erowid References Database
|
Mounteney J, Griffiths P, Bo A, Cunningham A, Matias J, Pirona A.
“Nine reasons why ecstasy is not quite what it used to be”.
Int J Drug Policy. 2017 Nov 20;51:36-41.
|
|
Abstract
This paper explores the recent resurgence in use of ecstasy/MDMA in Europe and highlights keys areas of continuity and divergence between the ecstasy market of the 1990s and the current MDMA market. Based on a scoping study involving a targeted multi-source data collection exercise on MDMA, it highlights nine areas that have undergone some level of change, linked with both supply and demand for the drug. Factors discussed include: innovation in production techniques; changes in precursor chemical availability; the role of online markets; competition with other stimulants and new psychoactive substances; the increased availability of high-strength MDMA; and the shift from subcultural towards more mainstream use of the drug. The paper proposes that the MDMA on Europe's contemporary market is in some respects a third generation product with a different consumer profile, with implications that responses developed at the time of the drug's earlier iteration, may be in need of a review and revamp.
|
| # |
| Submit Comment |
|
[
Cite HTML ]
